Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03971357 · ClinicalTrials.gov registry record · Phase 2
Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration
A Phase 2 study, sponsored by Price Vision Group.
- Terminated
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT03971357 is a Phase 2 study that was terminated before completion, run by Price Vision Group. The registered enrollment target is 19 participants.
The verdict
NCT03971357, a Phase 2 study, was terminated before completion, sponsored by Price Vision Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
Subjects with Fuchs dystrophy will be randomized to use either netarsudil or placebo eye drops to determine if the use of netarsudil accelerates migration of host peripheral corneal endothelial cells to restore the central endothelial cell layer.
Interventions
- DRUG Placebo
- DRUG Netarsudil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2019-07-22 |
| Est. Completion | 2021-08-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03971357
The ClinicalTrials.gov registry entry for NCT03971357 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Price Vision Group, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03971357 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03971357 about?
NCT03971357 is a clinical study titled "Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration". Subjects with Fuchs dystrophy will be randomized to use either netarsudil or placebo eye drops to determine if the use of netarsudil accelerates migration of host peripheral corneal endothelial cells to restore the central endothelial cell layer.
What is the current status of trial NCT03971357?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2019-07-22. Estimated completion is 2021-08-26.
What interventions are being tested in trial NCT03971357?
The interventions under investigation include: Placebo (DRUG), Netarsudil (DRUG).
Who is sponsoring clinical trial NCT03971357?
This trial is sponsored by Price Vision Group, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.